Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 60

Sort by

Sort Order Select

Journal Articles

Novel Drugs and Clinical Trial-Based Treatments Prolong Survival of Peripheral T-Cell Lymphomas (PTCL) Patients: Single Institution Retrospective Analysis

Helen Ma, MD, Enrica Marchi, MD, PhD, Bin Cheng, PhD, Govind Bhagat, MD, Owen A. O'Connor, MD PhD

Blood (2019) 134 (Supplement_1): 3486.

https://doi.org/10.1182/blood-2019-123587

Published: 2019

Journal Articles

Ex-Vivo Drug Response Profiling for Tailoring Treatment in Hematologic Malignancies: The Prospective Non-Interventional SMART-Trial

Nora Liebers, Peter-Martin Bruch, Agnes Gambietz, Holly Giles, BA, Junyan Lu, PhD, Mareike Knoll, Carolin Kolb, Peter Dreger, Carsten Mueller-Tidow, MD, Wolfgang Huber, PhD, Axel Benner, Thorsten Zenz, MD, Sascha Dietrich, MD

Blood (2019) 134 (Supplement_1): 376.

https://doi.org/10.1182/blood-2019-125324

Published: 2019

Journal Articles

Folate-Dependent Normocytic Anemia Caused By a Hypomorphic Mutation in SLC19A1 gene

Michael Svaton, MD, Karolina Skvarova Kramarzova, MSc, PhD, Veronika Kanderova, MSc, PhD, Petr Smisek, MD, Pavel Jesina, MSc, MD, PhD, Jakub Krijt, MSc, Blanka Stiburkova, MSc, PhD, Andrea Mancikova, MSc, Robert Dobrovolny, MSc, PhD, Violeta Bakardjieva-Mihaylova, MSc, Elena Vodickova, MD, Jan Stuchly, MSc, Tomas Kalina, MD PhD, Jan Stary, MD PhD, Jan Trka, MD PhD, Eva Fronkova, MD PhD, Viktor Kozich, MD PhD

Blood (2018) 132 (Supplement 1): 502.

https://doi.org/10.1182/blood-2018-99-113501

Published: 2018

Journal Articles

Pralatrexate in Combination with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Previously Untreated Patients with Peripheral T-Cell Lymphoma (PTCL): A Phase 1 Dose-Escalation Study

Andrei Shustov, MD, Patrick B Johnston, MD PhD, Stefan Klaus Barta, MDMRCP,MS, Gajanan Bhat, Guru Reddy, Yasuhiro Oki, MD

Blood (2017) 130 (Supplement 1): 818.

https://doi.org/10.1182/blood.V130.Suppl_1.818.818

Published: 2017

Journal Articles

CHOP in Combination with Pralatrexate, a Novel Folate Analogue Metabolic Inhibitor in Patients with Previously Untreated Peripheral T-Cell Lymphoma (PTCL): Interim Results of the Phase 1 Trial

Andrei R. Shustov, MD, Yasuhiro Oki, MD, Stefan Klaus Barta, MD MRCP, MS, Patrick B. Johnston, MD PhD, Pankaj Sharma, Tao Song, Sanjay Mourya

Blood (2016) 128 (22): 5355.

https://doi.org/10.1182/blood.V128.22.5355.5355

Published: 2016

Journal Articles

Farber S. Some observations on the effect of folic acid antagonists on acute leukemia and other forms of incurable cancer. Blood . 1949;4(2): 160-167 .

Blood (2016) 127 (3): 271.

https://doi.org/10.1182/blood-2015-12-685586

Published: 2016

Journal Articles

Effect of Intrathecal Methotrexate on CSF and RBC Folate Levels in Children Receiving Treatment for Acute Lymphoblastic Leukemia

Keith J. August, MD MS, Leon van Haandel, PhD, J. Steven Leeder, PharmD, PhD

Blood (2015) 126 (23): 2486.

https://doi.org/10.1182/blood.V126.23.2486.2486

Published: 2015

Journal Articles

Schedule-Dependent Synergy Between Belinostat and Pralatrexate in T-and B-Cell Lymphoma Cells in Vitro

Godefridus Peters, FHA van Gemert, I Kathmann, Saskia AGM Cillessen, MSc, G Jansen, Guru Reddy

Blood (2015) 126 (23): 5128.

https://doi.org/10.1182/blood.V126.23.5128.5128

Published: 2015

Journal Articles

An Open-Label, Phase 1 Study Evaluating the Safety and Pharmacokinetics of Pralatrexate in Relapsed/Refractory Advanced Solid Tumors or Advanced Lymphoma/Myeloma Patients with Mild, Moderate, and Severe Renal Impairment

Kevin R. Kelly, MD PhD, Nashat Y. Gabrail, MD, William J Edenfield, MD, A Craig Lockhart, Anthony J. Olszanski, MDPhD, Guru Reddy

Blood (2015) 126 (23): 3966.

https://doi.org/10.1182/blood.V126.23.3966.3966

Published: 2015

Journal Articles

High-Throughput Drug Screening Identifies Pyrimethamine As a Potent and Selective Inhibitor of Acute Myeloid Leukemia

Amit Sharma, PhD, Nidhi Jyotsana, Courteney K. Lai, BSc, Anuhar Chaturvedi, PhD, Kerstin Görlich, Cecilia Murphy, Jan E. Blanchard, Arnold Ganser, Eric Brown, John A. Hassell, R. Keith Humphries, MD PhD, Michael A Morgan, PhD, Michael Heuser, MD

Blood (2014) 124 (21): 2304.

https://doi.org/10.1182/blood.V124.21.2304.2304

Published: 2014

Journal Articles

Targeting of MDS and AML Stem Cells Via Inhibition of STAT3 By Pyrimethamine

Aditi Shastri, MD, Carolina Schinke, MD, Asya Varshavsky Yanovsky, MD PhD, Tushar D. Bhagat, PhD, Orsolya Giricz, Laura Barreyro, M.Sc., Jacqueline Boultwood, PhD, Andrea Pellagati, Yiting Yu, PhD, Jennifer R. Brown, MD PhD, David A. Frank, MD PhD, Bhaskar Das, PhD, Suman Kambhampati, MD, Britta Will, PhD, Ulrich Steidl, MDPhD, Amit Verma, MD

Blood (2014) 124 (21): 3602.

https://doi.org/10.1182/blood.V124.21.3602.3602

Published: 2014

Journal Articles

Pre-Clinical Analysis Of The Novel Antifolate Pralatrexate In Multiple Myeloma Reveals Functional Biomarkers Correlated With Response

Michael Mangone, PhD, Anna H Mei, BA, Luigi Scotto, PhD, Michele Visentin, PhD, Enrica Marchi, MD, PhD, I. David Goldman, MD, Constantine S. Mitsiades, MD, PhD, Owen A. O'Connor, MD, PhD, Hearn J. Cho, MD, PhD

Blood (2013) 122 (21): 4430.

https://doi.org/10.1182/blood.V122.21.4430.4430

Published: 2013

Journal Articles

Pcft Is Silenced By DNA Methylation In Pediatric Acute Lymphoblastic Leukemia Resulting In Decreased Methotrexate Uptake

Calvin K. Lee, MD, Weijie Poh, Megan Healey, PhD, Eric S Schafer, MD, Patrick Brown, MD, James G. Herman, MD

Blood (2013) 122 (21): 3768.

https://doi.org/10.1182/blood.V122.21.3768.3768

Published: 2013

Journal Articles

Cutaneous Toxicity Associated with Pralatrexate in Cutaneous and Peripheral T-Cell Lymphoma

Terri L. Parker, MD, Lisa Barbarotta, APRN-BC, Michael Girardi, MD, FAAD, Francine M. Foss, MD

Blood (2012) 120 (21): 3660.

https://doi.org/10.1182/blood.V120.21.3660.3660

Published: 2012

Journal Articles

A Phase I/II Study of Bortezomib (VELCADE) in Combination with Pralatrexate in Relapsed/Refractory Multiple Myeloma

Tamara J. Dunn, MD, Shira N. Dinner, MD, Caroline Berube, MD, Jason Gotlib, MD, MS, Steven E. Coutre, MD, Bruno C. Medeiros, MD, Michaela Liedtke, MD

Blood (2012) 120 (21): 4304.

https://doi.org/10.1182/blood.V120.21.4304.4304

Published: 2012

Journal Articles

Clinico-Pathologic Characteristics of Patients Experiencing Severe Pyrimethamine Poisoning

Mercedes Gasior, Hasan Ahmad, Stephen M. Hart, PhD, Christopher J McNamara, -

Blood (2012) 120 (21): 5162.

https://doi.org/10.1182/blood.V120.21.5162.5162

Published: 2012

Journal Articles

Pralatrexate Has Potent Activity Against Multiple Myeloma In Vitro and In Vivo , and Activity Correlates with Tumor RFC-1 and DHFR Expression

Michael Mangone, AB, Luigi Scotto, Ph.D., Enrica Marchi, MD, Ph.D., Owen A. O'Connor, MD, PhD, Hearn J. Cho, MD, PhD

Blood (2011) 118 (21): 1831.

https://doi.org/10.1182/blood.V118.21.1831.1831

Published: 2011

Journal Articles

Associations of Methylene Tetrahydrofolate Reductase Polymorphism and Methotrexate-Related Toxicities in Korean Treated for Malignant Lymphoma

Hyangmin Park, Dok Hyun Yoon, MD, Youngcheon Song, Heese Kim, Youngseol Huh, Shin Kim, R.N, Seongsoo Jang, MD, Chan-Jeoung Park, Hyun-Sook Chi, MD., Ph.D., Chan-Sik Park, Jooryung Huh, MD, Sang-wook Lee, Cheolwon Suh, MD

Blood (2011) 118 (21): 1607.

https://doi.org/10.1182/blood.V118.21.1607.1607

Published: 2011

Journal Articles

SLCO1B1 Variation and Methotrexate Disposition in Children with Acute Lymphoblastic Leukemia: The Importance of Rare Variants in Pharmacogenetics

Laura B. Ramsey, PhD, Gitte H Bruun, Wenjian Yang, PhD, Lisa R Trevino, PhD, Selina Vattathil, Paul Scheet, PhD, Cheng Cheng, PhD, Gary Rosner, Kathleen Giacomini, PhD, Yiping Fan, PhD, Alex Sparreboom, PhD, Torben Mikkelsen, MD PhD, Thomas J Corydon, PhD, Ching-Hon Pui, MD, William E. Evans, PharmD, Mary V. Relling, PharmD

Blood (2011) 118 (21): 571.

https://doi.org/10.1182/blood.V118.21.571.571

Published: 2011

Journal Articles

Efficacy of Short Oral Leucovorin Rescue (SOLR) In Managing Recurrent Pralatrexate (Folotyn) Induced Mucositis (RPIM) Despite Dose Reduction

Philip A Haddad, MD

Blood (2011) 118 (21): 4745.

https://doi.org/10.1182/blood.V118.21.4745.4745

Published: 2011

NARROW

Novel Drugs and Clinical Trial-Based Treatments Prolong Survival of Peripheral T-Cell Lymphomas (PTCL) Patients: Single Institution Retrospective Analysis

Ex-Vivo Drug Response Profiling for Tailoring Treatment in Hematologic Malignancies: The Prospective Non-Interventional SMART-Trial

Folate-Dependent Normocytic Anemia Caused By a Hypomorphic Mutation in SLC19A1 gene

Pralatrexate in Combination with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Previously Untreated Patients with Peripheral T-Cell Lymphoma (PTCL): A Phase 1 Dose-Escalation Study

CHOP in Combination with Pralatrexate, a Novel Folate Analogue Metabolic Inhibitor in Patients with Previously Untreated Peripheral T-Cell Lymphoma (PTCL): Interim Results of the Phase 1 Trial

Farber S. Some observations on the effect of folic acid antagonists on acute leukemia and other forms of incurable cancer. Blood . 1949;4(2): 160-167 .

Effect of Intrathecal Methotrexate on CSF and RBC Folate Levels in Children Receiving Treatment for Acute Lymphoblastic Leukemia

Schedule-Dependent Synergy Between Belinostat and Pralatrexate in T-and B-Cell Lymphoma Cells in Vitro

An Open-Label, Phase 1 Study Evaluating the Safety and Pharmacokinetics of Pralatrexate in Relapsed/Refractory Advanced Solid Tumors or Advanced Lymphoma/Myeloma Patients with Mild, Moderate, and Severe Renal Impairment

High-Throughput Drug Screening Identifies Pyrimethamine As a Potent and Selective Inhibitor of Acute Myeloid Leukemia

Targeting of MDS and AML Stem Cells Via Inhibition of STAT3 By Pyrimethamine

Pre-Clinical Analysis Of The Novel Antifolate Pralatrexate In Multiple Myeloma Reveals Functional Biomarkers Correlated With Response

Pcft Is Silenced By DNA Methylation In Pediatric Acute Lymphoblastic Leukemia Resulting In Decreased Methotrexate Uptake

Cutaneous Toxicity Associated with Pralatrexate in Cutaneous and Peripheral T-Cell Lymphoma

A Phase I/II Study of Bortezomib (VELCADE) in Combination with Pralatrexate in Relapsed/Refractory Multiple Myeloma

Clinico-Pathologic Characteristics of Patients Experiencing Severe Pyrimethamine Poisoning

Pralatrexate Has Potent Activity Against Multiple Myeloma In Vitro and In Vivo , and Activity Correlates with Tumor RFC-1 and DHFR Expression

Associations of Methylene Tetrahydrofolate Reductase Polymorphism and Methotrexate-Related Toxicities in Korean Treated for Malignant Lymphoma

SLCO1B1 Variation and Methotrexate Disposition in Children with Acute Lymphoblastic Leukemia: The Importance of Rare Variants in Pharmacogenetics

Efficacy of Short Oral Leucovorin Rescue (SOLR) In Managing Recurrent Pralatrexate (Folotyn) Induced Mucositis (RPIM) Despite Dose Reduction

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only